ProfileGDS5678 / 1436420_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 86% 86% 85% 85% 85% 82% 84% 82% 84% 83% 84% 85% 87% 82% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.3983586
GSM967853U87-EV human glioblastoma xenograft - Control 26.5940586
GSM967854U87-EV human glioblastoma xenograft - Control 36.4287985
GSM967855U87-EV human glioblastoma xenograft - Control 46.5397785
GSM967856U87-EV human glioblastoma xenograft - Control 56.4883485
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.7851482
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.125284
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.9088482
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.2169384
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.1601183
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.2454184
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.3625185
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.6738387
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.9638282